- Home
- FTNT vs EW Comparison
FTNT vs EW Comparison
Compare FTNT & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTNT | EW |
|---|---|---|
| Founded | 2000 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.1B | 49.5B |
| IPO Year | 2009 | 2000 |
Fundamental Metrics
Financial Performance| Metric | FTNT | EW |
|---|---|---|
| Price | $79.13 | $82.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 30 | 21 |
| Target Price | $91.11 | ★ $96.79 |
| AVG Volume (30 Days) | ★ 6.5M | 3.7M |
| Earning Date | 02-05-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.04 | N/A |
| EPS | ★ 2.43 | 2.33 |
| Revenue | ★ $6,554,700,000.00 | $5,883,800,000.00 |
| Revenue This Year | $15.69 | $14.29 |
| Revenue Next Year | $11.18 | $9.73 |
| P/E Ratio | ★ $33.46 | $35.47 |
| Revenue Growth | ★ 14.78 | 10.60 |
| 52 Week Low | $70.12 | $65.94 |
| 52 Week High | $114.82 | $87.89 |
Technical Indicators
Market Signals| Indicator | FTNT | EW |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 42.50 |
| Support Level | $79.74 | $80.44 |
| Resistance Level | $82.36 | $84.69 |
| Average True Range (ATR) | 2.11 | 1.80 |
| MACD | 0.34 | -0.24 |
| Stochastic Oscillator | 48.48 | 28.58 |
Price Performance
Historical ComparisonAbout FTNT Fortinet Inc.
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.